200 related articles for article (PubMed ID: 25521641)
21. [Pharmaceutical pricing; what is reasonable?].
Versteegh MM
Ned Tijdschr Geneeskd; 2020 Aug; 164():. PubMed ID: 32940991
[TBL] [Abstract][Full Text] [Related]
22. Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania.
Lopert R; Ruiz F; Chalkidou K
Health Policy; 2013 Oct; 112(3):202-8. PubMed ID: 23953877
[TBL] [Abstract][Full Text] [Related]
23. The End of the International Reference Pricing System?
Persson U; Jönsson B
Appl Health Econ Health Policy; 2016 Feb; 14(1):1-8. PubMed ID: 26112982
[TBL] [Abstract][Full Text] [Related]
24. The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price.
Mladsi D; Barnett CL; Mader G; Russell-Smith TA; Unuigbe A; Bell T
Value Health; 2023 Mar; 26(3):384-391. PubMed ID: 36706950
[TBL] [Abstract][Full Text] [Related]
25. Resistance diagnosis and the changing economics of antibiotic discovery.
McAdams D
Ann N Y Acad Sci; 2017 Jan; 1388(1):18-25. PubMed ID: 28072904
[TBL] [Abstract][Full Text] [Related]
26. Drug pricing and value in oncology.
Danzon PM; Taylor E
Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
[TBL] [Abstract][Full Text] [Related]
27. Pricing schemes for new drugs: a welfare analysis.
Levaggi R
Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
[TBL] [Abstract][Full Text] [Related]
28. What is a new drug worth? An innovative model for performance-based pricing.
Dranitsaris G; Dorward K; Owens RC; Schipper H
Eur J Cancer Care (Engl); 2015 May; 24(3):313-20. PubMed ID: 25256668
[TBL] [Abstract][Full Text] [Related]
29. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
30. Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.
Messori A
Clin Drug Investig; 2016 Aug; 36(8):599-603. PubMed ID: 27216427
[TBL] [Abstract][Full Text] [Related]
31. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of the cost and effectiveness of generic and brand-name antibiotics: the case of uncomplicated urinary tract infection.
Lin YS; Jan IS; Cheng SH
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):301-309. PubMed ID: 27862588
[TBL] [Abstract][Full Text] [Related]
33. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
JAMA Oncol; 2015 Dec; 1(9):1293-300. PubMed ID: 26313558
[TBL] [Abstract][Full Text] [Related]
34. [Medical problems associated with the national reference pricing system in Hungary].
Kerpel-Fronius S
Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
[TBL] [Abstract][Full Text] [Related]
35. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
36. The impact of pricing and patent expiration on demand for pharmaceuticals: an examination of the use of broad-spectrum antimicrobials.
Kaier K
Health Econ Policy Law; 2013 Jan; 8(1):7-20. PubMed ID: 22947241
[TBL] [Abstract][Full Text] [Related]
37. Drug Pricing in South Korea.
Kwon HY; Godman B
Appl Health Econ Health Policy; 2017 Aug; 15(4):447-453. PubMed ID: 28138932
[TBL] [Abstract][Full Text] [Related]
38. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
39. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
[TBL] [Abstract][Full Text] [Related]
40. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
Simoens S; Decramer M; Laekeman G
Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
